Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy.
Bristol Myers sees revenue decline in its legacy drug portfolio due to competition and Medicare headwinds.
Oops, something went wrong
Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Bristol Myers sees revenue decline in its legacy drug portfolio due to competition and Medicare headwinds.